New research finds obesity speeds up development of dementia

By Stephen Beech

Obesity speeds up the development of dementia, reveals new research.

The first study evaluating the impact of obesity on Alzheimer’s disease blood biomarkers (BBMs) was conducted by American scientists.

The high-tech blood tests showed that BBM values increased up to 95% faster in obese people than in people who weren't seriously overweight.

Study senior author Professor Cyrus Raji said: “This is the first time we’ve shown the relationship between obesity and Alzheimer’s disease as measured by blood biomarker tests."

The research team accessed five-year data on 407 participants from the Alzheimer’s Disease Neuroimaging Initiative, which included amyloid positron emission tomography (PET) scans and blood samples.

PET scans show the brain’s amyloid burden, or the accumulation of beta-amyloid protein in the brain in the form of amyloid plaques, a hallmark of Alzheimer’s disease.

Plasma samples were tested for BBMs associated with Alzheimer’s.

These included levels of pTau217 - a biomarker used in the diagnosis and monitoring of Alzheimer’s, neurofilament light chain (NfL) - a protein fragment released from damaged or dying neurons, and plasma GFAP - a protein expressed primarily in astrocytes, cells that support and protect neurons in the brain and spinal cord, using six leading commercial tests.

The research team performed statistical analysis to assess the association between the BBMs and body mass index (BMI) and the three-way interaction between obesity, time and BBMs.

The team also validated the BBMs against the amyloid PET scans.

Analysis of the BBMs and PET scan data showed that at the outset, BMI was associated with lower BBMs and reduced whole-brain amyloid burden.

Study lead author Dr. Soheil Mohammadi, said: “We believe the reduced BBMs in obese individuals was due to dilution from the higher blood volume.

“In fact, by relying on the baseline measurements, you could be fooled into thinking that the people with obesity had a lower pathology of Alzheimer’s disease.

"We need the longitudinal data to fully understand the how obesity impacts the development of Alzheimer’s pathology.”

A longitudinal study involves repeatedly collecting data from the same group over an extended period of time, tracking changes and trends.

Over time, Alzheimer’s disease BBMs and brain PET scans showed an increased burden of Alzheimer’s disease pathology in obese people compared with non-obese individuals.

Participants with obesity had a 29% to 95% faster rate of increase in plasma pTau217 ratio levels.

Baseline obesity led to a 24% faster rate of increase in plasma NfL and a 3.7% faster rate of increase in amyloid accumulation, according to the findings.

Raji, of Washington University School of Medicine in St. Louis, says the analysis showed that the blood tests were more sensitive than the PET scans in capturing the impact of obesity on Alzheimer’s pathology.

He said: “The fact that we can track the predictive influence of obesity on rising blood biomarkers more sensitively than PET is what astonished me in this study."

Dr. Mohammadi says the impact of obesity on trajectories of amyloid burden and corresponding changes in blood biomarkers for Alzheimer’s is an "important" consideration for clinical practice.

He added: “According to the 2024 report of the Lancet Commission, 14 modifiable risk factors total approximately 45%, or close to half, of the risk for Alzheimer’s disease.

“If we can reduce any of those risk factors, we can significantly reduce Alzheimer’s cases or lengthen the amount of time until the onset of the disease.”

Raji believes longitudinal assessments with blood biomarkers with brain health imaging will become the norm for monitoring treatment paradigms with anti-amyloid drugs.

He added: “This is such profound science to follow right now because we have drugs that can treat obesity quite powerfully, which means we could track the effect of weight loss drugs on Alzheimer’s biomarkers in future studies.

“It’s marvelous that we have these blood biomarkers to track the molecular pathology of Alzheimer’s disease, and MRI scans to track additional evidence of brain degeneration and response to various treatments.

"This work is foundational for future studies and treatment trials.”

The findings are due to be presented at the annual meeting of the Radiological Society of North America (RSNA) in Chicago.